An update from Aptose Biosciences ( (TSE:APS) ) is now available.
On April 1, 2025, Aptose Biosciences announced that its common shares will be delisted from the Nasdaq Stock Market effective April 2, 2025, due to non-compliance with the equity requirement. Despite the delisting, Aptose plans to continue its business operations and seek listing on another U.S. national securities exchange while its shares remain listed on the TSX.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. Their pipeline includes small molecule cancer therapeutics designed for single-agent efficacy and to enhance other anti-cancer therapies without overlapping toxicities. Their lead compound, tuspetinib (TUS), is an oral kinase inhibitor for acute myeloid leukemia (AML).
YTD Price Performance: -53.40%
Average Trading Volume: 220,944
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.16M
See more data about APS stock on TipRanks’ Stock Analysis page.